OncoMune Names New CSO
OncoMune, a provider of targeted cancer therapeutics, has appointed Christopher Dougherty, research professor at Florida Atlantic University, as its new chief scientific officer.
Dr Dougherty has a doctorate in molecular and cellular pharmacology from the University of Miami Miller School of Medicine.
Boris Reznik, chairman of OncoMune, said: “Dr Dougherty has made many scientific advances in cellular biology as a member of the research faculty in the College of Biomedical Science at Florida Atlantic University. We are eager to add his talents and experience as we continue to develop cancer vaccines and RNA interference based therapeutics.”